SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma rises on entering into agreements to acquire stakes in Agatsa Software, Remidio Innovative Solutions

20 Feb 2023 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 986.05, up by 2.50 points or 0.25% from its previous closing of Rs. 983.55 on the BSE.

The scrip opened at Rs. 990.00 and has touched a high and low of Rs. 992.15 and Rs. 974.75 respectively. So far 13122 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022.

Last one week high and low of the scrip stood at Rs. 1017.85 and Rs. 974.75 respectively. The current market cap of the company is Rs. 236550.43 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.01% and 9.51% respectively.

Sun Pharmaceutical Industries has entered into agreements to acquire equity shares (up to 26.09%) of Agatsa Software, which is an early-stage digital diagnostic devices company and to acquire equity shares (27.39%) of Remidio Innovative Solutions, which provides innovative products enabling early detection of eye diseases.

The company has entered into agreements to acquire minority stake in Agatsa Software and Remidio Innovative Solutions which are non-material investments by the Company in the allied areas.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1668.00 -7.20 (-0.43%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×